Polymer-Based Solutions for Effective In Vivo mRNA Delivery
At RJH Biosciences, we develop non-viral, polymer-based delivery platforms engineered for efficient and reproducible mRNA delivery across in vivo biological systems. Our technologies support functional mRNA expression in animal models and are designed to enable systemic delivery, consistent performance, and broad applicability across research and therapeutic development programs.
In vivo biodistribution of mRNA delivered with RJH reagents mRNA-Fect and mRNA-Fect kit. Systemic administration demonstrates effective tissue-level delivery, highlighting the versatility of RJH reagents beyond traditional LNP-based approaches.
| In Vivo mRNA Delivery with RJH Reagent mRNA-Fect Demonstrates Functional Activity Left: Relative tumor volume following treatment with TRAIL or control mRNA demonstrates clear differences due to mRNA payloads.Right: Tumor weights at study endpoint further confirm the biological activity achieved through mRNA-Fect-mediated mRNA delivery. |
|---|
About RJH Biosciences
RJH Biosciences is a biotechnology company based in Edmonton, Alberta, Canada, specializing in non-viral nucleic acid delivery systems for research and therapeutic development. Our polymer-based transfection reagents — including mRNA-Fect, mRNA-Fect Kit, and mRNA-Fect In Vivo — are engineered for reliable mRNA delivery across a wide range of cell types and in vivo animal models, offering a cost-effective and reproducible alternative to lipid nanoparticle (LNP)-based approaches.
Our platforms support delivery of mRNA, siRNA, pDNA, miRNA, ASOs, and CRISPR-Cas9 ribonucleoproteins (RNPs), and are trusted by researchers across North America, Europe, Asia, and beyond through our global distributor network.
Explore our products: mRNA transfection reagents | in vivo mRNA delivery | CRISPR transfection reagents | siRNA delivery systems
